Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

1. A compound having formula (I)

wherein

A 1 is CR 1 ;

A 2 is CR 2 ;

A 3 is CR 3 ;

A 4 is CR 4 ;

R 1 , R 2 , R 3 and R 4 are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, halogen, hydrogen, hydroxy, alkoxy, —OR c , haloalkoxy, NR A R B , —C(O)R a , —C(O)OH, —C(O)Oalkyl, —S(alkyl), —S(O)alkyl, —S(O) 2 R a , R c , —O-alkyl-R c and alkyl-R c ;

X is O;

Y is a bond;

L is a bond;

R a is alkyl, haloalkyl, —NH 2 , —N(H)(alkyl), —N(alkyl) 2 , R c , or -alkyl-R c ;

m is 0;

n is 2;

R 7 and R 8 , at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, heteroaryl, cycloalkyl, cycloalkenyl, and alkyl-R c , wherein the heteroaryl, cycloalkyl and cycloalkenyl are each independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from the group consisting of alkyl, haloalkyl, halogen, alkoxy, haloalkoxy, —NH 2 , —N(H)(alkyl), —N(alkyl) 2 , —N(H)C(O)alkyl, —N(alkyl)C(O)alkyl, —N(H)C(O)alkyl, N(alkyl)C(O)Oalkyl, —C(O)alkyl, —C(O)OH, —C(O)Oalkyl, —C(O)NH 2 , —C(O)N(H)(alkyl), —C(O)N(alkyl) 2 , —S(alkyl), —S(O)alkyl, —S(O) 2 alkyl, —S(O) 2 N(H) 2 , —S(O) 2 N(H)(alkyl) and —S(O) 2 N(alkyl) 2 , provided that when R 7 and R 8 are on a carbon atom that is not adjacent to X, the alkyl is other than methyl;

R 9 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy or haloalkoxy;

R A and R B are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, R c , and -alkyl-R c ;

Z is a monocyclic or bicyclic ring selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycle, heteroaryl and aryl; wherein each Z is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from the group consisting of alkyl, haloalkyl, halogen, hydroxy, alkoxy, haloalkoxy, —NH2, —N(H)(alkyl), —N(alkyl) 2 , —C(O)alkyl, —C(O)OH, —C(O)Oalkyl, —C(O)NH 2 , C(O)N(H)(alkyl), —C(O)N(alkyl) 2 , —S(alkyl), —S(O)alkyl, —S(O) 2 alkyl, —S(O) 2 N(H) 2 , —S(O) 2 N(H)(alkyl), —S(O) 2 N(alkyl) 2 , R c , and alkoxyalkyl;

provided that when A 1 is CR 1 , A 2 is CR 2 , A 3 is CR 3 , A 4 is CR 4 , Y is a bond, L is a bond, X is O, and the sum of m and n is 2 then Z is a bicyclic ring selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycle and heteroaryl; wherein each Z is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from the group consisting of alkyl, haloalkyl, halogen, hydroxy, alkoxy, haloalkoxy, —NH 2 , —N(H)(alkyl), —N(alkyl) 2 , —C(O)alkyl, —C(O)OH, —C(O)Oalkyl, —C(O)NH 2 , —C(O)N(H)(alkyl), —C(O)N(alkyl) 2 , —S(alkyl), —S(O)alkyl, —S(O) 2 alkyl, —S(O) 2 N(H) 2 , —S(O) 2 N(H)(alkyl), —S(O) 2 N(alkyl ) 2 , R c , and alkoxyalkyl; and

R c at each occurrence is independently a monocyclic or bicyclic ring, independently selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycle, heteroaryl and aryl;

wherein each R c is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from the group consisting of alkyl, haloalkyl, halogen, oxo, hydroxy, alkoxy, haloalkoxy, —NH 2 , —N(H)(alkyl), —N(alkyl) 2 , —N(H)C(O)alkyl, —N(alkyl)C(O)alkyl, —N(H)C(O)Oalkyl, —N(alkyl)C(O)Oalkyl, —C(O)alkyl, —C(O)OH, —C(O)Oalkyl, —C(O)NH 2 , —C(O)N(H)(alkyl), —C(O)N(alkyl) 2 , —S(alkyl), —S(O)alkyl, —S(O) 2 alkyl, —S(O) 2 N(H) 2 , —S(O) 2 N(H)(alkyl) and —S(O)2N(alkyl) 2 .

2. The compound of claim 1 , wherein Z is a bicyclic ring selected from the group consisting of cycloalkenyl, cycloalkyl, heterocycle and heteroaryl.

3. The compound of claim 2 wherein Z is heteroaryl.

4. The compound of claim 3 , wherein Z is heteroaryl selected from the group consisting of benzimidazolyl, indazolyl, isoquinolinyl, and quinolinyl.

5. The compound of claim 4 , wherein

Z is indazolyl;

R 7 and R 8 , at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, and -alkyl-R c as described in claim 1 ;

A 1 is CR 1 ;

A 2 is CR 2 ;

A 3 is CR 3 ; and

A 4 is CR 4 ; wherein R 1 , R 2 , R 3 and R 4 as described in claim 1 .

6. The compound of claim 5 wherein indazolyl is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents as described in claim 1 ;

L is a bond;

X is O;

Y is a bond;

m is 0; and

n is 2.

7. The compound of claim 6 that is selected from the group consisting of:

N-(7-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

N-1H-indazol-4-yl-N′-(6-methyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(6-chloro-7-methyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-3,4-dihydro-2H-chromen-4-yl-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-[8-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

methyl 4-[({[8-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

methyl 4-[({[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

(−)-N-1H-indazol-4-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

(+)-N-1H-indazol-4-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

methyl 4-({[(8-piperidin-1-yl-3,4-dihydro-2H-chromen-4-yl)amino]carbonyl}amino)-1H-indazole-1-carboxylate;

N-1H-indazol-4-yl-N′-(8-piperidin-1-yl-3,4-dihydro-2H-chromen-4-yl)urea;

N-1H-indazol-4-yl-N′-(8-morpholin-4-yl-3,4-dihydro-2H-chromen-4-yl)urea;

methyl 4-({[(8-morpholin-4-yl-3,4-dihydro-2H-chromen-4-yl)amino]carbonyl}amino)-1H-indazole-1-carboxylate;

methyl 4-({[(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)amino]carbonyl}amino)-1H-indazole-1-carboxylate;

N-(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

methyl 4-[{[8-chloro-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

N-[8-chloro-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-1H-indazol-4-ylurea;

(+)-N-(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

(−)-N-(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

methyl 4-[({[8-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

N-1H-indazol-4-yl-N′-[8-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]urea;

methyl 4-[({[8-fluoro-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

N-[8-fluoro-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N′-1H-indazol-4-ylurea;

methyl 4-({[(8-cyclohexyl-3,4-dihydro-2H-chromen-4-yl)amino]carbonyl}amino)-1H-indazole-1-carboxylate;

N-(8-cyclohexyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

methyl 4-[({[7-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

N-1H-indazol-4-yl-N′-[7-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]urea;

N-(6-fluoro-2-methyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-1H-indazol-4-yl-N′-(7-methoxy-2-phenyl-3,4-dihydro-2 H-chromen-4-yl)urea;

N-1H-indazol-4-yl-N′-(7-methoxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-1H-indazol-4-yl-N′-(7-methoxy-2,2,8-trimethyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-1H-indazol-4-yl-N′-(2,2,8-trimethyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-1H-indazol-4-yl-N′-(7-methoxy-2,2-dimethyl-8-propyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-(2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(7-fluoro-2,2-diethyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(7,8-difluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-[7-(3,3-dimethylbutyl)-3,4-dihydro-2H-chromen-4-yl]-N′-1H-indazol-4-ylurea;

N-(7-tert-butyl-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(2,2-diethyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-( l-methyl-1H-indazol-4-yl)urea;

N-(7,8-difluoro-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(7-fluoro-2,2-dipropyl-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(2,2-dibutyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(2-tert-butyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-1H-indazol-4-ylurea;

N-(1-ethyl-1H-indazol-4-yl)-N′-(7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-(2-tert-butyl-7-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-( 1-methyl-1H-indazol-4-yl)urea;

N-(2-ethyl-2H-indazol-4-yl)-N′-(7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)urea; and

N-(7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N′-[ 1-(2-methoxyethyl)-1H-indazol-4-yl]urea.

8. The compound of claim 4 , wherein

Z is isoquinolinyl;

R 7 and R 8 , at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, and alkyl-R c as described in claim 1 ;

A 1 is CR 1 ;

A 2 is CR 2 ;

A 3 is CR 3 ; and

A 4 is CR 4 ; wherein R 1 , R 2 , R 3 and R 4 are as described in claim 1 .

9. The compound of claim 8 wherein isoquinolinyl is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents as described in claim 1 ;

L is a bond;

X is O;

Y is a bond;

m is 0; and

n is 2.

10. The compound of claim 9 that is selected from the group consisting of:

N-isoquinolin-5-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

N-isoquinolin-5-yl-N′-(6-methyl-3,4-dihydro-2H-chromen-4-yl)urea;

N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-isoquinolin-5-ylurea;

N-(6-chloro-7-methyl-3,4-dihydro-2H-chromen-4-yl)-N′-isoquinolin-5-ylurea;

N-(7-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-(3-methylisoquinolin-5-yl)urea;

N-(6-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-(3-methylisoquinolin-5-yl)urea;

N-isoquinolin-5-yl-N′-(8-piperidin-1-yl-3,4-dihydro-2H-chromen-4-yl)urea; (+)-N-isoquinolin-5-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea; and

(−)-N-isoquinolin-5-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea.

11. The compound of claim 4 , wherein

Z is quinolinyl;

R 7 and R 8 , at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, and alkyl-Rc as described in claim 1 ;

A 1 is CR 1 ;

A 2 is CR 2 ;

A 3 is CR 3 ; and

A 4 is CR 4 ; wherein R 1 , R 2 , R 3 and R 4 as described in claim 1 .

12. The compound of claim 11 wherein quinolinyl is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents as described in claim 1 ;

L is a bond;

X is O;

Y is a bond;

m is 0;

n is 2.

13. The compound of claim 12 that is selected from the group consisting of:

N-(7-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-quinolin-5-ylurea;

N-(7-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N′-quinolin-8-ylurea;

N-quinolin-5-yl-N′-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea;

N-(6-methyl-3,4-dihydro-2H-chromen-4-yl)-N′-quinolin-5-ylurea;

N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-quinolin-5-ylurea;

N-(6-chloro-7-methyl-3,4-dihydro-2H-chromen-4-yl)-N′-quinolin-5-ylurea;

N-(6-methyl-3,4-dihydro-2H-chromen-4-yl)-N′-quinolin-8-ylurea; and

N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N′-quinolin-8-ylurea.

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof.

15. A method of treating a disorder wherein the disorder is ameliorated by inhibiting vanilloid receptor subtype 1 (VR1) receptor in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, and wherein the disorder is selected from the group consisting of pain, bladder overactivity and urinary incontinence.

16. The method of claim 15 wherein the disorder is selected form the group consisting of acute pain, chronic pain, inflammatory pain, osteoarthritic pain, cancer pain, lower back pain, bladder overactivity and urinary incontinence.

17. The method of claim 15 wherein the disorder is selected form the group consisting of acute pain, chronic pain, inflammatory pain, osteoarthritic pain, cancer pain, lower back pain, bladder overactivity and urinary incontinence.

18. The method of claim 15 wherein the disorder is bladder overactivity.

19. The method of claim 15 wherein the disorder is urinary incontinence.

20. The method of claim 15 wherein the disorder is osteoarthritic pain.

21. The method of claim 15 wherein the disorder is inflammatory pain.